Q3 2024 EPS Estimates for Repligen Co. Cut by William Blair (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Analysts at William Blair lowered their Q3 2024 earnings estimates for shares of Repligen in a research report issued to clients and investors on Tuesday, July 30th. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $0.33 per share for the quarter, down from their previous forecast of $0.42. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share. William Blair also issued estimates for Repligen’s FY2024 earnings at $1.44 EPS, Q1 2025 earnings at $0.48 EPS, Q3 2025 earnings at $0.52 EPS and FY2025 earnings at $2.16 EPS.

Other equities research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and cut their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. UBS Group lowered their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday. Guggenheim initiated coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $190.00 target price on shares of Repligen in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $189.57.

Repligen Stock Performance

RGEN opened at $161.67 on Friday. The company has a market cap of $9.06 billion, a price-to-earnings ratio of 646.71, a PEG ratio of 5.98 and a beta of 0.95. The firm’s fifty day simple moving average is $134.92 and its two-hundred day simple moving average is $166.00. The company has a quick ratio of 5.24, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same period in the previous year, the business earned $0.53 earnings per share. The business’s revenue was down 3.2% compared to the same quarter last year.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently modified their holdings of RGEN. Norges Bank acquired a new stake in shares of Repligen during the fourth quarter worth about $48,208,000. Bank of New York Mellon Corp increased its stake in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares during the last quarter. Public Employees Retirement Association of Colorado grew its holdings in shares of Repligen by 448.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock worth $20,293,000 after buying an additional 92,268 shares during the last quarter. Finally, Brown Capital Management LLC increased its position in Repligen by 5.8% in the 4th quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after acquiring an additional 83,416 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity

In related news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Martin D. Madaus purchased 1,615 shares of Repligen stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the transaction, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.